MedTrace Logo

Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia

NCT00138736 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2007-08-30

No results posted yet for this study

Summary

The pharmacokinetics, and clinical and biological effects of MBL replacement therapy in MBL-deficient children during chemotherapy-induced neutropenia were studied.

Conditions

Interventions

DRUG

Mannan Binding Lectin (MBL)

DRUG

Mannan Binding Lectin

MBL dose at a twice weekly dose interval (3 or 4 days): 0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval

Sponsors & Collaborators

  • Landsteiner Foundation for Blood Transfusion

    collaborator OTHER

  • Prothya Biosolutions

    lead INDUSTRY

Principal Investigators

  • T W Kuijpers, MD, PdD · Dept. of Paediatric Immunology, AMC, Amsterdam, The Netherlands

  • H N Caron · Dept of Paediatric Oncology, AMC, Amsterdam, The Netherlands

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Completion
2006-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00138736 on ClinicalTrials.gov